EDGAR·FLOW

Pacira BioSciences, Inc. — Form 8-K

Filed October 8, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 79/100
What the filing says
Viatris Inc. and its subsidiary Peach Purchaser Sub Inc. entered into a definitive merger agreement with Pacira BioSciences dated October 8, 2026, to acquire all outstanding Pacira shares at $36.50 per share in an all-cash tender offer, valuing the company at approximately $1.46 billion (based on 39.9M shares outstanding as of October 7, 2026, excluding treasury shares). The merger will proceed via a two-step process: first a cash tender offer for all shares, then a statutory merger under DGCL Section 251(h) without stockholder vote. Pacira's board unanimously approved the transaction and recommended stockholders tender their shares.
Why this rating

Acquisition at fixed $36.50/share price provides certainty for Pacira shareholders. Deal size (~$1.46B enterprise value) is ~193% of Pacira's market cap (~$757.5M), materially altering company trajectory. Transaction substantial relative to company size and constitutes business-changing M&A event.

Tradability signal
NO TRADE

No trade: positive news with only -0.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.60% over 4 hrs, n=174). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$36.34 ▲ 0.08%
at our read · unknown
$36.31
+10 min · unknown
$36.28 ▼ 0.07%
+30 min · unknown
$36.30 ▼ 0.03%
+1 hr · unknown
$36.30 ▼ 0.01%
+4 hrs
pending

The stock had already moved -0.08% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ PCRX · stock on Yahoo Finance ↗

See more from October 8, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.